Nicholas Hoffman & Company LLC. Buys Shares of 1,562 Agilent Technologies, Inc. (NYSE:A)

Nicholas Hoffman & Company LLC. bought a new stake in Agilent Technologies, Inc. (NYSE:AFree Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,562 shares of the medical research company’s stock, valued at approximately $217,000.

A number of other large investors also recently bought and sold shares of the stock. Money Concepts Capital Corp acquired a new stake in shares of Agilent Technologies during the fourth quarter worth about $26,000. MV Capital Management Inc. lifted its position in shares of Agilent Technologies by 120.7% during the fourth quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after purchasing an additional 105 shares in the last quarter. Ancora Advisors LLC acquired a new stake in shares of Agilent Technologies during the fourth quarter worth about $34,000. OFI Invest Asset Management acquired a new stake in shares of Agilent Technologies during the third quarter worth about $25,000. Finally, Baystate Wealth Management LLC lifted its position in shares of Agilent Technologies by 107.3% during the fourth quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after purchasing an additional 133 shares in the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, SVP Philip Binns sold 2,827 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the completion of the sale, the senior vice president now owns 9,997 shares of the company’s stock, valued at $1,474,957.38. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, SVP Philip Binns sold 2,827 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the completion of the transaction, the senior vice president now owns 9,997 shares in the company, valued at $1,474,957.38. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael R. Mcmullen sold 52,297 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $150.00, for a total value of $7,844,550.00. Following the completion of the transaction, the chief executive officer now owns 253,909 shares of the company’s stock, valued at approximately $38,086,350. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,610 shares of company stock valued at $9,220,333. 0.33% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Evercore ISI increased their price target on shares of Agilent Technologies from $132.00 to $145.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Citigroup upped their target price on shares of Agilent Technologies from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. Oppenheimer upped their target price on shares of Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 26th. UBS Group upped their target price on shares of Agilent Technologies from $130.00 to $155.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. Finally, Stifel Nicolaus upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and increased their price target for the company from $145.00 to $163.00 in a research note on Friday, April 5th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $141.29.

View Our Latest Stock Analysis on A

Agilent Technologies Price Performance

Shares of NYSE A opened at $132.73 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04. The stock has a fifty day moving average price of $141.18 and a 200 day moving average price of $129.92. Agilent Technologies, Inc. has a 1-year low of $96.80 and a 1-year high of $151.58. The company has a market cap of $38.90 billion, a PE ratio of 31.60, a P/E/G ratio of 4.02 and a beta of 1.11.

Agilent Technologies (NYSE:AGet Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.07. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The firm had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.59 billion. During the same period last year, the company earned $1.37 earnings per share. The company’s revenue for the quarter was down 5.5% on a year-over-year basis. Sell-side analysts forecast that Agilent Technologies, Inc. will post 5.51 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd will be issued a $0.236 dividend. This represents a $0.94 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Monday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.38%.

Agilent Technologies Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Further Reading

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:AFree Report).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.